Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

J Control Release. 2024 Apr:368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.

Abstract

Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by "decorating" and "pruning". This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors.

Keywords: Adoptive cellular immunotherapy; CAR-M; CAR-NK; CAR-T; Chimeric antigen receptor; Solid tumor.

Publication types

  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms* / pathology
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes
  • Tumor Microenvironment

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell